Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease

Clicks: 382
ID: 270102
2011
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #4 of 10 articles by views in alimentary pharmacology & therapeutics

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Clinical efficacy and normalised CRP at week 12 (early deep clinical remission) are associated with medium-term clinical efficacy and mucosal healing during adalimumab therapy, whereas need for combined immunosuppression at induction and smoking status are predictors for non-response. Parallel azath …
Reference Key
ls2011alimentaryearly Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kiss LS;Szamosi T;Molnar T;Miheller P;Lakatos L;Vincze A;Palatka K;Barta Z;Gasztonyi B;Salamon A;Horvath G;Tóth GT;Farkas K;Banai J;Tulassay Z;Nagy F;Szenes M;Veres G;Lovasz BD;Vegh Z;Golovics PA;Szathmari M;Papp M;Lakatos PL; ;;
Journal alimentary pharmacology & therapeutics
Year 2011
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.